VIDEO: Tremfya induces clinical remission, endoscopic improvement at week 12 in UC
Click Here to Manage Email Alerts
A greater proportion of patients treated with Tremfya for moderate to severe ulcerative colitis achieved clinical remission at 12 weeks compared with placebo, according to Axel Dignass, MD, PhD, presenting author of a clinical study.
Data from the phase 2b QUASAR induction study showed more than 60% of patients treated with Tremfya (guselkumab, Janssen) achieved the primary endpoint of clinical response at week 12, with 30% of patients also achieving endoscopic improvement.
“This promising and exciting QUASAR study shows that in patients with moderately to severely active UC, guselkumab can induce clinical and meaningful improvement compared to placebo across several endpoints, including clinical response, clinical remission and even histo-endoscopic improvement at week 12,” Dignass, professor of medicine and gastroenterology at Agaplesion Markus Hospital at Goethe University in Germany, said. “The efficacy and safety of the two tested doses, 200 mg and 400 mg IV, were comparable and overall, no safety signals for guselkumab were observed. ... We as clinicians look forward to the maintenance data.”
Phase 3 clinical trials for Tremfya in the treatment of moderate to severe UC are ongoing and currently enrolling participants.
Collapse
Dignass A, et al. Abstract OP23. Presented at: Congress of European Crohn’s and Colitis Organization; Feb.16-19, 2022 (virtual meeting).
Read more about
Click Here to Manage Email Alerts